Breaking News Instant updates and real-time market news.

ACET

Aceto

$7.40

(0.00%)

, NVS

Novartis

$81.72

(0.00%)

09:37
04/19/18
04/19
09:37
04/19/18
09:37

Wells says bottom has not been reached in generics pricing

After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).

ACET

Aceto

$7.40

(0.00%)

NVS

Novartis

$81.72

(0.00%)

TEVA

Teva

$17.91

(0.00%)

MYL

Mylan

$40.73

(0.00%)

  • 23

    Apr

  • 27

    Apr

  • 17

    May

  • 18

    May

  • 21

    May

  • 05

    Jun

  • 16

    Jun

  • 13

    Nov

ACET Aceto
$7.40

(0.00%)

04/19/18
ADAM
04/19/18
DOWNGRADE
ADAM
Sell
Aceto downgraded to Sell from Buy at Canaccord
07/31/17
ADAM
07/31/17
INITIATION
Target $19
ADAM
Buy
Aceto initiated with a Buy at Canaccord
Canaccord Genuity analyst Dewey Steadman started Aceto with a Buy rating and $19 price target. The analyst likes the company's "unique" asset-light business model strategy.
08/28/17
ADAM
08/28/17
NO CHANGE
Target $15
ADAM
Buy
Aceto price target lowered to $15 from $19 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Aceto to $15 from $19 following Q3 earnings. The analyst said its bottom-line performance was disappointing due to a meaningful step-down in gross margins due to low-margin launches and continued contributions from its Citron acquisition. Steadman maintained his Buy rating on Aceto shares as he is still positive on its potential for growth driven by new product launches and product approvals.
04/19/18
ADAM
04/19/18
DOWNGRADE
Target $2
ADAM
Sell
Aceto double downgraded to Sell at Canaccord
As reported previously, Canaccord analyst Dewey Steadman downgraded Aceto two notches, to Sell from Buy, citing a rapid degradation of the company's asset-light business model in the wake of continued pressures for commoditized generics. The company's core human health business has been under significant pressure and has been unable to swiftly adapt to market conditions, said Steadman, who lowered his price target to $2 from $10 on Aceto shares after the company last night said it was suspending further guidance and reducing its dividend.
NVS Novartis
$81.72

(0.00%)

04/18/18
JEFF
04/18/18
DOWNGRADE
Target $218
JEFF
Hold
AveXis downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded AveXis (AVXS) to Hold while raising his price target for the shares to $218 from $141. The analyst's downgrade and new price target reflect the pending acquisition by Novartis (NVS).
04/16/18
ROTH
04/16/18
NO CHANGE
Target $27
ROTH
Buy
CymaBay seladelpar a 'clear winner' from EASL, says Roth Capital
Roth Capital analyst Yasmeen Rahimi notes that Novartis (NVS) reported disappointing 28-day interim results from its FXR agonist in 49 PBC patients at EASL. Tropifexor had AP level drops far below CymaBay's (CBAY) seldelpar at 4 weeks, she points out, adding that she believes seladelpar is a "clear winner" from Paris. Rahimi reiterates a Buy rating and $27 price target on CymaBay's shares.
04/12/18
LEHM
04/12/18
DOWNGRADE
Target $218
LEHM
Equal Weight
AveXis downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded AveXis (AVXS) to Equal Weight to reflect the proposed takeover by Novartis (NVS). The analyst sees limited antitrust risks and a low probability of a counterbid. She raised her price target for AveXis shares to $218 from $152. She believes the price being paid by Novartis fully reflects the value of the stock.
04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
TEVA Teva
$17.91

(0.00%)

02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
02/21/18
DBAB
02/21/18
NO CHANGE
Target $20
DBAB
Hold
Deutsche sees rifamycin as possible long-term threat to Valeant
The outlook for Valeant Pharmaceuticals' (VRX) Xifaxan, which represents 13% of the company's revenue, improved last year following safety issues for competitor Viberzi and delays for generic challenger Teva (TEVA), Deutsche Bank analyst Gregg Gilbert tells investors in a research note. More recently, the analyst notes, questions have been raised as to whether Cosmo's rifamycin could pose a threat to Xifaxan, either in the near term from off-label prescribing for irritable bowel syndrome with diarrhea, or longer term if eventually approved for IBS-D. After due diligence, Gilbert believes rifamycin could potentially be a longer-term threat to Xifaxan if it works for IBS-D, but he does not see "material risk" from off-label use in the interim. His model continues to assume mid-single digit Xifaxan sales growth for several years and a generic cliff in 2025. The analyst keeps a Hold rating on Valeant with a $20 price target.
03/20/18
JEFF
03/20/18
INITIATION
Target $19
JEFF
Hold
Teva resumed with a Hold at Jefferies
Jefferies analyst David Steinberg resumed coverage of Teva Pharmaceutical with a Hold rating and $19 price target. The analyst sees "headwinds on multiple fronts" and believes the positive outlook for Austedo and fremanezumab is priced in with the shares trading at 10 times 2020 consensus EBITDA.
03/26/18
RBCM
03/26/18
NO CHANGE
Target $16
RBCM
Sector Perform
RBC Capital concerned with 'overly ambitious' consensus assumptions for Teva
RBC Capital analyst Randall Stanicky lowered his price target on Teva to $16 from $18, saying that his own model contrasts with "overly optimistic" consensus regarding the P&L assumptions in the company's Branded segment. Specifically, the analyst is concerned with the rising generic competition for Teva's Copaxone as well as fremanezumab, which he expects to miss the June 16 PDUFA "given Celltrion's outstanding Warning Letter" while lowering his peak sales projections by $200M to $1B. Stanicky keeps his Sector Perform rating on Teva, adding that the multi-year turnaround investment thesis on the stock is not supported at this point.
MYL Mylan
$40.73

(0.00%)

04/12/18
JPMS
04/12/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan shares remain 'highly inexpensive,' says JPMorgan
JPMorgan analyst Chris Schott says his positive longer term thesis is unchanged following Mylan's investor day. Commentary on the near-term pipeline remained upbeat and Mylan highlighted multiple long-term revenue drivers, Schott tells investors in a research note. He believes the company's "significant" generic Advair opportunity, as well as other potential near-term approvals, more than offset any downside risk from ongoing challenges in the U.S. generics market. The analyst thinks Mylan shares remain "highly inexpensive." Schott keeps an Overweight rating on the name with a $53 price target.
04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
04/12/18
UPGRADE
Target $52

Outperform
Mylan upgraded to Outperform at Leerink
As previously reported, Leerink analyst Ami Fadia upgraded Mylan to Outperform from Market Perform, with a $52 price target, citing valuation disconnect given the diversified business and catalyst path.
04/18/18
LEHM
04/18/18
NO CHANGE
Target $230
LEHM
Overweight
Barclays sees 'significant challenges' for Botox biosimilar
Barclays analyst Douglas Tsao says that while he'd probably stop short of calling it "mission impossible," he sees "significant challenges" in the development of a biosimilar to Allergan's (AGN) Botox. Following a deep dive into the key issues Mylan (MYL) will likely face in developing a biosimilar Botox, the analyst and concluded that it seems "technically difficult and faces a long road ahead." Even a best case scenario puts timing out to 2023, Tsao tells investors in a research note. The analyst has an Overweight rating on Allergan with a $230 price target.

TODAY'S FREE FLY STORIES

CYAD

Celyad

$29.00

(0.00%)

07:09
05/25/18
05/25
07:09
05/25/18
07:09
Initiation
Celyad initiated  »

Celyad initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$85.50

0.5 (0.59%)

07:07
05/25/18
05/25
07:07
05/25/18
07:07
Initiation
SAIC initiated  »

SAIC initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 21

    Jun

CJ

C&J Energy Services

$28.78

-0.8 (-2.70%)

07:07
05/25/18
05/25
07:07
05/25/18
07:07
Initiation
C&J Energy Services initiated  »

C&J Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SVRA

Savara

$8.55

0.02 (0.23%)

07:06
05/25/18
05/25
07:06
05/25/18
07:06
Initiation
Savara initiated  »

Savara initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

07:05
05/25/18
05/25
07:05
05/25/18
07:05
General news
FX Update: The dollar has been trading mixed »

FX Update: The dollar has…

AZN

AstraZeneca

$36.88

0.035 (0.09%)

07:04
05/25/18
05/25
07:04
05/25/18
07:04
Hot Stocks
AstraZeneca announces PACIFIC trial meets overall survival endpoint »

AstraZeneca and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

MANT

ManTech

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Initiation
ManTech initiated  »

ManTech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACBFF

Aurora Cannabis

$0.00

(0.00%)

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Hot Stocks
Aurora Cannabis retains KCSA for U.S. investor relations efforts »

Aurora Cannabis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$116.35

-0.2 (-0.17%)

07:03
05/25/18
05/25
07:03
05/25/18
07:03
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SPX

S&P 500

$0.00

(0.00%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$82.95

0.35 (0.42%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Recommendations
Ross Stores analyst commentary  »

Ross Stores weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.64

0.28 (1.25%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$81.55

0.48 (0.59%)

, EBAY

eBay

$37.79

-0.25 (-0.66%)

07:02
05/25/18
05/25
07:02
05/25/18
07:02
Recommendations
PayPal, eBay analyst commentary  »

PayPal price target…

PYPL

PayPal

$81.55

0.48 (0.59%)

EBAY

eBay

$37.79

-0.25 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 12

    Jun

GLD

SPDR Gold Trust

$123.61

1.07 (0.87%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGL

Engility

$30.17

0.33 (1.11%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Initiation
Engility initiated  »

Engility initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$26.22

1.04 (4.13%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$14.87

0.54 (3.77%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.22

-0.99 (-4.09%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.36

-1.79 (-3.64%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$185.96

-0.94 (-0.50%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Periodicals
Zuckerberg says 'vast majority' of users opt into invasive features, BI reports »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

VXX

iPath S&P 500 VIX Short-Term Futures

$33.82

-0.18 (-0.53%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$83.75

-0.4 (-0.48%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Upgrade
Canadian National rating change  »

Deutsche upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ARLP

Alliance Resource Partners

$18.25

-0.45 (-2.41%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Conference/Events
Alliance Resource Partners management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SPLK

Splunk

$116.35

-0.2 (-0.17%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

-0.02 (-0.42%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.